Catalyst Event
Natera Inc (NTRA) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/16/2026, 12:00:00 AM
The Executive Chairman sold approximately $38.3 million in shares under a 10b5-1 plan between March 12 and 16, 2026; a ~1% price impact is estimated as planned insider sales are generally neutral.
Korean Translation
2026년 3월 12일부터 16일 사이 회장이 Rule 10b5-1 계획에 따라 주식을 매도함. 계획된 매도는 시장 영향이 약 1% 내외로 미미할 것으로 예상됨.
Related Recent Events
Ionis Pharmaceuticals Inc (IONS) · Other
FDA target action (PDUFA) date for olezarsen for the treatment of severe hypertriglyceridemia (sHTG) following acceptance of sNDA for Priority Review. This is a major potential approval for a broad patient population, scheduled.
6/30/2026, 12:00:00 AM
Biogen Inc (BIIB) · Earnings Release
Q1 2026 earnings release (Low impact estimated as routine earnings releases typically see at least 1% volatility) scheduled.
5/6/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Bristol-Myers Squibb is scheduled to announce its first-quarter 2026 financial results on April 30, 2026, scheduled.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled; a price impact of at least 1% is expected.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva is scheduled to release its first quarter 2026 financial results and host a conference call on April 29, 2026; importance is estimated at Medium as earnings reports typically drive significant price volatility, expected.
4/29/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
First quarter 2026 earnings results are scheduled to be released on April 23, 2026. This is expected to have a low impact as a routine financial update, scheduled.
4/23/2026, 12:00:00 AM